There were 1,964 press releases posted in the last 24 hours and 429,913 in the last 365 days.

Amarantus BioSciences' CEO Scheduled to Appear on The Big Biz Radio Show

Amarantus BioSciences' CEO Gerald Commissiong Scheduled to Appear on The Big Biz Radio Show

/EINPresswire.com/ SUNNYVALE, CA - January 12, 2012 - Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing MANF, a first-in-class disease-modifying therapeutic protein, today announced the company will be a featured guest on The Big Biz Radio Show on Thursday, March 15, 2012 at 10:20 AM Pacific. The live broadcast can be accessed via the show's website: http://bigbizshow.com/media/ . Amarantus' previous four appearances on the Big Biz Show and other CEO interviews are available for viewing online at http://www.amarantus.com/investor-relations/videos.html .
The Big Biz Show is a nationwide radio broadcast featuring commentators Bob Sullivan and Russ Nailz who discuss topics including current events, business trends, investment opportunities, innovations in headline making industries, and hot stock picks.

About Amarantus BioSciences, Inc.

Amarantus BioSciences, Inc. is a California-based development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat Parkinson's disease and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF"). For further information please visit www.amarantus.com.

MEDIA CONTACTS:

Gerald E. Commissiong
pr@amarantus.com
408-737-2734 ext. 102

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.